Jamie L. Felton
Biochemistry, Genetics and Molecular Biology · Indiana University
Publications
62
Citations
1,044
Est. group size
~2
Recurring co-author estimate
Active years
20
Publishing since 2007
Jamie L. Felton studies type 1 diabetes, an autoimmune disease in which the body's immune system attacks the insulin-producing cells of the pancreas. The research focuses on how immune cells (especially B cells and T cells) drive the disease, how to predict and screen for it before symptoms appear, and how drugs or immunotherapies might slow or prevent its onset.
Publication activity has grown notably over the last decade, rising from a few papers per year to roughly a dozen annually in recent years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Type I Interferons as Contextual Regulators of B-Cell Tolerance in Type 1 Diabetes
Biomolecules · 2026
- Response to letter to the editor from Thea and Buschard: “Progression from stage 1 to stage 3 type 1 diabetes characterized by hypoglycemia”
JCEM Case Reports · 2026
- Pharmacological inhibition of tyrosine protein-kinase 2 reduces islet inflammation and delays type 1 diabetes onset in mice
EBioMedicine · 2025
- Establishing Screening Programs for Presymptomatic Type 1 Diabetes: Practical Guidance for Diabetes Care Providers
The Journal of Clinical Endocrinology & Metabolism · 2025
- Type 1 Diabetes TrialNet: Leading the Charge in Disease Prediction, Prevention, and Immunotherapeutic Mechanistic Understanding
Diabetes Care · 2025
- Autoimmune origin for immune checkpoint inhibitor-diabetes revealed by deep immune phenotyping of the pancreas
Journal for ImmunoTherapy of Cancer · 2025
- SAT-603 Progression from Stage 1 to Stage 3 Type 1 Diabetes with Predominant Hypoglycemia
Journal of the Endocrine Society · 2025
- Progression from Stage 1 to Stage 3 Type 1 Diabetes Characterized by Hypoglycemia
JCEM Case Reports · 2025
- Altered B cell metabolic pathways characterize type 1 diabetes progression
The Journal of Immunology · 2025
- Pharmacological inhibition of tyrosine protein-kinase 2 reduces islet inflammation and delays type 1 diabetes onset in mice
bioRxiv (Cold Spring Harbor Laboratory) · 2024
- Altered B Cell Metabolic Pathways Characterize Type 1 Diabetes Progression
bioRxiv (Cold Spring Harbor Laboratory) · 2024
- Pharmacological Inhibition of Tyrosine Protein-Kinase 2 Reduces Islet Inflammation and Delays Type 1 Diabetes Onset in Mice
SSRN Electronic Journal · 2024
- Cellular Metabolism in B Cells in Type 1 Diabetes
Proceedings of IMPRS · 2023
- B Quiet: Autoantigen-Specific Strategies to Silence Raucous B Lymphocytes and Halt Cross-Talk with T Cells in Type 1 Diabetes
Biomedicines · 2021
- Timing of Immunotherapy in Type 1 Diabetes: The Earlier, the Better?
ImmunoHorizons · 2021
- Communications Medicine×16
- The Journal of Immunology×8
- Diabetes Care×3
- Diabetes×2
- medRxiv×2
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile